Alembic Pharma gets final nod from USFDA for infection treatment drug

Alembic Pharmaceuticals

Drug firm Alembic Pharmaceuticals on Tuesday said it has received a final nod from the US health regulator for Azithromycin tablets, used for the treatment of infections.

"Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Azithromycin Tablets USP, 600 mg," the drug firm said in a filing to BSE.

Azithromycin tablet is a macrolide antibacterial drug indicated for mild to moderate infections.

The approved ANDA is therapeutically equivalent to the reference listed drug product Zithromax tablets, 600 mg, of Pfizer, the filing said.

Citing IQVIA, the company said Azithromycin tablets USP, 600 mg have an estimated market size of $2 million for 12 months ending September 2019.

Alembic Pharmaceuticals has a cumulative total of 115 ANDA approvals (103 final approvals and 12 tentative approvals) from USFDA.

The shares of the company were trading at Rs 628.35 a piece on BSE in morning trade, up 2.20 per cent from the previous close.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel